11-oxo-mogroside V

11-oxo-mogroside V is a natural sweetener that exhibits strong antioxidant activity. It exhibits significant inhibitory effects on reactive oxygen species ( O 2 - , H 2 O 2 and *OH ) with EC 50 of 4.79, 16.52, and 146.17 μg/mL, respectively.In Vitro11-oxo-mogroside V shows a higher scavenging effect on O 2 - (concentration at which 50% of chemiluminescence intensity is inhibited [EC 50 ]=4.79 μg/mL) and H 2 O 2 (EC 50 =16.52 μg/mL) than those of mogroside V. 11-oxo-mogroside V exhibits a remarkable inhibitory effect on *OH-induced DNA damage with EC 50 =3.09 μg/mL.11-oxo-mogroside V, a natural sweetener, isolated from the fruits of Momordica grosvenori , exhibits strong inhibitory effect on the primary screening test indicated by the induction of Epstein-Barr virus early antigen (EBV-EA) by a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). 11-oxo-mogroside V exhibits strong inhibitory effect on EBV-EA induction (91.2, 50.9 and 21.3% inhibition at 1000, 500 and 100 mol ratio/TPA concentration, respectively). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoIn the group treated with DMBA, TPA and 11-oxo-mogroside V, only 26.6 and 53.3% of mice bore papillomas even at 10 and 15 weeks of promotion, respectively, and only 1.0 3.3 and 4.7 papillomas are formed per mouse at 10, 15 and 20 weeks of promotion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal administrationMice Specific pathogen-free female ICR (6 weeks old) and female SENCAR (6 weeks old) mice are use. The animals (female SENCAR, 6 weeks old) are divided into three groups, 15 mice each. The back of each mouse is shaved with surgical clipper, and the mice are topically treated with peroxynitrite (33.1 μg, 390 nmol, 1 mM NaOH) in acetone (0.1 mL) as an initiation treatment. For groups I (control group) II and III, 1 week after initiation with peroxynitrite, mice are promoted by the application with TPA (1 mg, 1.7 nmol) in acetone (0.1 mL) twice a week. For groups II and III, mogroside V and 11-oxo-mogroside V (0.0025%, 2.5 mg/100 mL) in drinking water is given orally, from 1 week before to 1 week after the initiation treatment with peroxynitrite, respectively. The incidence of papillomas is observed weekly for 20 weeks; the percentages of mice bearing papillomas and the average number of papillomas per mouse are recorded. The type of tumors in our experiment is also checked by the pathologist with the histological examination, and the malignant tumors are not observed at 20 weeks of promotion in our experimental system. The tumor incidence is statistically analyzed by Student's t-test in treated mice and controls. aladdin has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:EC50: 4.79 μg/mL (O 2 - ), 16.52 μg/mL (H 2 O 2 ), 146.17 μg/mL (*OH)

Specifictaions: Moligand™, ≥99%

MDL Number: C60H100O29

Molecular Formula: 1285.42

PubChem CID: 122706002

UPC:

51172410

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

O651363-25mg

CAS:

126105-11-1

Product Size:

25mg